Sunitinib-CLIO Conjugate: A VEGFR/PDGFR-Targeting Active MR Probe
Cited 0 times inCited 0 times in
- Sunitinib-CLIO Conjugate: A VEGFR/PDGFR-Targeting Active MR Probe
- Noh, Gwang Tae; Kim, Mi-Hyun; Suh, Ji-Yeon; Song, Youngkyu; Lee, Chang Kyung; Baek, Jin Hee; Lee, Yong Seok; Cho, Gyunggoo; Kim, Eunju; Kim, Young Ro; Cho, Hyungjoon; Lim, Dongyeol; Kim, Jeong Kon
- Issue Date
- MOLECULAR IMAGING AND BIOLOGY, v.16, no.3, pp.340 - 349
- This study was conducted to evaluate feasibility of sunitinib-CLIO conjugate as a vascular endothelial growth factor receptor/platelet-derived growth factor receptor (VEGFR/PDGFR)-specific magnetic resonance (MR) probe.
VEGFR/PDGFR-targeting MR probe was synthesized by conjugating cross-linked iron-oxide (CLIO) with tyrosine-kinase inhibitor (sunitinib). In VEGFR/PDGFR-positive (U118MG) and VEGFR/PDGFR-negative (HT29) cells and tumor models, conjugate-driven Delta R (2) was estimated, while CLIO was used as control. Prussian-blue staining was performed for quantifying the amount of tumor-binding conjugates.
Delta R (2) between sunitinib-CLIO-treated and non-treated cells was greater in U118MG (mean, 2.1/s) than in HT29 cells (1.0/s). In in vivo study, conjugate induced a greater Delta R (2) in U118MG (11.2/s) than HT29 tumors (5.9/s). Conjugate-induced R (2) changes were not correlated with degree of Gd-DTPA enhancement, demonstrating that tumor binding of sunitinib-CLIO was independent of enhanced permeability and retention effect. % area of Prussian-blue staining was greater in U118MG (8.5 %) than in HT29 (1.4 %).
Sunitinib-CLIO conjugate can be used as an active MR probe for quantifying VEGFR/PDGFR.
- Appears in Collections:
- BME_Journal Papers
- Files in This Item:
- There are no files associated with this item.
can give you direct access to the published full text of this article. (UNISTARs only)
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.